<DOC>
	<DOCNO>NCT00057837</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . It yet know combination chemotherapy regimen effective treat extensive-stage small cell lung cancer . PURPOSE : Randomized phase II trial compare effectiveness two combination chemotherapy regimens treat patient extensive-stage small cell lung cancer .</brief_summary>
	<brief_title>Comparison Two Combination Chemotherapy Regimens Treating Patients With Extensive-Stage Small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Evaluate response frequency patient extensive stage small cell lung cancer treat topotecan , cisplatin , etoposide irinotecan , cisplatin , etoposide . - Evaluate toxic effect regimens patient . - Evaluate duration response survival patient treat regimen . Secondary - To investigate occurrence various breast cancer resistance protein ( BCRP ) alleles patient receive topoisomerase 1 inhibitor impact clinical response toxicity . OUTLINE : This randomize , multicenter study . Patients randomize 1 2 treatment arm . - Arm I ( PET ) : Patients receive topotecan intravenously ( IV ) 30 minute day 1-3 ; etoposide IV 60 minute immediately follow cisplatin IV 60 minute day 8-10 ; filgrastim ( G-CSF ) subcutaneously daily begin day 11 continue blood count recover . - Arm II ( PIE ) : Patients receive irinotecan IV 90 minute cisplatin IV 60 minute day 1 8 oral etoposide twice daily day 3 10 . In arm , treatment repeat every 3 week 6 course absence disease progression unacceptable toxicity . Patients follow every 3 month 2 year every 6 month 1 year . ACTUAL ACCRUAL : A total 140 patient accrue study .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<mesh_term>Podophyllotoxin</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<mesh_term>Topoisomerase Inhibitors</mesh_term>
	<criteria>INCLUSION CRITERIA : Extensive stage small cell lung cancer ( SCLC ) measurable disease , evaluate within 2 week prior randomization Eastern Cooperative Oncology Group ( ECOG ) performance status 03 Diseasefree &gt; =5 year prior second malignancy treat basal cell squamous cell skin cancer , carcinoma situ cervix Adequate hematologic , hepatic renal function determine follow test , within 4 week prior randomization : white blood cell ( WBC ) &gt; =4000/mm3 platelet &gt; =100,000/mm3 ; bilirubin &lt; = upper limit normal ; serum glutamic pyruvate transaminase ( SGPT ) alanine transaminase ( ALT ) serum glutamic oxaloacetic transaminase ( SGOT ) aspartate transaminase ( AST ) &lt; =2.5 x upper limit normal demonstrable liver metastasis &lt; =5 time upper limit normal presence liver metastases ; Calculated creatinine clearance &gt; =30 use formula protocol Age 18 old Strongly advise use accept effective method contraception Those central nervous system ( CNS ) metastases eligible metastasis treat without advance symptom prior initiation chemotherapy Those receive erythropoietin could continue receive EXCLUSION CRITERIA : Prior radiotherapy lung cancer ; Prior radiotherapy allow central nervous system ( CNS ) metastases Prior chemotherapy disease Pregnant lactating</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>extensive stage small cell lung cancer</keyword>
	<keyword>Topotecan</keyword>
	<keyword>Etoposide</keyword>
	<keyword>Cisplatin</keyword>
	<keyword>Irinotecan</keyword>
</DOC>